pharmaphorum2 年
Actinium eyes filing as conditioning drug for AML aces trial
Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.
Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal
Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...
Nature3 年
Turning radiation into a tumor-seeking missile
Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...
pharmaphorum2 年
Actinium radioligand aces AML trial as filings beckon
Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...
Business Insider1 个月
H.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $4.00. The company’s ...